Poseida Therapeutics Surges Over 223% on Roche's $1.5 Billion Acquisition Deal

Gelonghui November 26 | Poseida Therapeutics (PSTX.US) surged over 223%, trading at $9.25. On the news front, Roche announced on Tuesday that it would acquire U.S.-based biopharmaceutical company Poseida Therapeutics at $9 per share, with a total equity value of $1 billion post-acquisition. If specific milestones are achieved, shareholders will also receive non-tradable contingent value rights (CVR) worth $4 per share, bringing the total transaction value to approximately $1.5 billion. The deal is expected to close in the first quarter of 2025. (Gelonghui)